Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) and Rallybio (NASDAQ:RLYB – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.
Volatility & Risk
Aligos Therapeutics has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500. Comparatively, Rallybio has a beta of -0.72, indicating that its share price is 172% less volatile than the S&P 500.
Institutional & Insider Ownership
60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 10.3% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Aligos Therapeutics and Rallybio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aligos Therapeutics | $2.19 million | 13.62 | -$24.19 million | ($7.30) | -0.65 |
| Rallybio | $860,000.00 | 102.74 | -$8.98 million | ($4.34) | -3.83 |
Rallybio has lower revenue, but higher earnings than Aligos Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings for Aligos Therapeutics and Rallybio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aligos Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
| Rallybio | 0 | 1 | 0 | 0 | 2.00 |
Aligos Therapeutics presently has a consensus price target of $38.50, indicating a potential upside of 705.44%. Given Aligos Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Aligos Therapeutics is more favorable than Rallybio.
Profitability
This table compares Aligos Therapeutics and Rallybio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aligos Therapeutics | -241.01% | -160.72% | -92.30% |
| Rallybio | -911.07% | -40.53% | -38.13% |
Summary
Aligos Therapeutics beats Rallybio on 8 of the 15 factors compared between the two stocks.
About Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
About Rallybio
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
